This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Avivagen Beheer

Beheer criteriumcontroles 3/4

Avivagen's CEO is G. F. Anthony, appointed in Feb 2017, has a tenure of 7.42 years. directly owns 0.84% of the company’s shares, worth CA$3.27K. The average tenure of the management team and the board of directors is 7.3 years and 14.9 years respectively.

Belangrijke informatie

G. F. Anthony

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	7.4yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	7.3yrs
Gemiddelde ambtstermijn bestuur	14.9yrs

Recente managementupdates

Recent updates

It's Unlikely That Avivagen Inc.'s (CVE:VIV) CEO Will See A Huge Pay Rise This Year

Apr 02

Analyse CEO-vergoeding

Hoe is G. F. Anthony's beloning veranderd ten opzichte van Avivagen's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jul 31 2023	n/a	n/a	-CA$5m
Apr 30 2023	n/a	n/a	-CA$6m
Jan 31 2023	n/a	n/a	-CA$6m
Oct 31 2022	CA$400k	CA$361k	-CA$6m
Jul 31 2022	n/a	n/a	-CA$6m
Apr 30 2022	n/a	n/a	-CA$6m
Jan 31 2022	n/a	n/a	-CA$7m
Oct 31 2021	CA$539k	CA$469k	-CA$6m
Jul 31 2021	n/a	n/a	-CA$6m
Apr 30 2021	n/a	n/a	-CA$5m
Jan 31 2021	n/a	n/a	-CA$5m
Oct 31 2020	CA$420k	CA$362k	-CA$5m
Jul 31 2020	n/a	n/a	-CA$5m
Apr 30 2020	n/a	n/a	-CA$5m
Jan 31 2020	n/a	n/a	-CA$5m
Oct 31 2019	CA$412k	CA$362k	-CA$5m
Jul 31 2019	n/a	n/a	-CA$5m
Apr 30 2019	n/a	n/a	-CA$5m
Jan 31 2019	n/a	n/a	-CA$5m
Oct 31 2018	CA$431k	CA$363k	-CA$5m
Jul 31 2018	n/a	n/a	-CA$5m
Apr 30 2018	n/a	n/a	-CA$5m
Jan 31 2018	n/a	n/a	-CA$5m
Oct 31 2017	CA$447k	CA$266k	-CA$5m

Compensatie versus markt: Insufficient data to establish whether G. F.'s total compensation is reasonable compared to companies of similar size in the Canadian market.

Compensatie versus inkomsten: G. F.'s compensation has been consistent with company performance over the past year.

CEO

G. F. Anthony (68 yo)

7.4yrs

Tenure

CA$399,892

Compensatie

Mr. G. F. Kym Anthony has been Chief Executive Officer of Avivagen Inc. since May 2019 serves as its Director since April 4, 2014 and serves as its Vice Chairman since April 19, 2023. Mr. Anthony served as...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
G. F. Anthony	CEO & Vice Chairman	7.4yrs	CA$399.89k	0.84% CA$ 3.3k
Graham Burton	Co-Founder	7.3yrs	CA$134.37k	0.47% CA$ 1.8k
Ira Levy	Interim Chief Financial Officer	1.8yrs	CA$120.38k	geen gegevens
James Nickerson	President and Executive VP of Business Development & Product Innovation	2.5yrs	geen gegevens	geen gegevens
Drew Basek	Director of Investor Relations	7.4yrs	geen gegevens	geen gegevens
Tracy Gillett	Director of Companion Animal & Marketing Manager	no data	geen gegevens	geen gegevens

7.3yrs

Gemiddelde duur

Ervaren management: VIV.H's management team is seasoned and experienced (7.3 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
G. F. Anthony	CEO & Vice Chairman	10.3yrs	CA$399.89k	0.84% CA$ 3.3k
Graham Burton	Co-Founder	18.9yrs	CA$134.37k	0.47% CA$ 1.8k
Murray McLaughlin	Member of Business & Technology Advisory Team	14.9yrs	geen gegevens	geen gegevens
Christopher Newman	Member of Scientific Advisory Board	17.4yrs	geen gegevens	geen gegevens
David Hankinson	Independent Chairman of the Board	18.9yrs	CA$71.17k	0.029% CA$ 113.0
Richard Smith	Member of Business and Technology Advisory Team	14.9yrs	geen gegevens	geen gegevens
Paul Mesburis	Independent Lead Director	8.3yrs	CA$97.13k	0.028% CA$ 109.9
Jolyon Burton	Member of Business and Technology Advisory Team	14.9yrs	geen gegevens	geen gegevens
Joseph Dunn	Member of Business and Technology Advisory Team	14.9yrs	geen gegevens	geen gegevens
John Oliver	Chairman of the Business and Technology Advisory Team	14.9yrs	geen gegevens	geen gegevens
John Brennan	Member of Business and Technology Advisory Team	14.9yrs	geen gegevens	geen gegevens

14.9yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: VIV.H's board of directors are seasoned and experienced ( 14.9 years average tenure).

This company listing is no longer active

Avivagen Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Avivagen Inc., Annual General Meeting, Apr 19, 2023

Insufficient new directors

Avivagen Inc. Appoints Ira Levy as Interim CFO

Insufficient new directors

Avivagen Inc., Annual General Meeting, Apr 08, 2022

Recent updates

Insufficient new directors

Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 3Q 2022)

Second quarter 2023 earnings released: CA$0.016 loss per share (vs CA$0.022 loss in 2Q 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Avivagen Inc., Annual General Meeting, Apr 19, 2023

Insufficient new directors

Avivagen Inc. announced that it expects to receive CAD 1 million in funding

Avivagen Inc. Appoints Ira Levy as Interim CFO

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Avivagen Announces Successful Completion of Formal Safety and Toxicology Evaluation of Fully Oxidized Beta-Carotene (OxBC)

Avivagen Inc. Announces Oxidized Carotenoid-Based Feed Additive Product Receive Approval for Use in China

Insufficient new directors

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Avivagen Inc. announced that it has received CAD 5.678 million in funding

Avivagen Announces Approval in Vietnam

Avivagen Inc., Annual General Meeting, Apr 08, 2022

Avivagen Inc., Annual General Meeting, Apr 08, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

No longer forecast to breakeven

Third quarter 2021 earnings released: CA$0.026 loss per share (vs CA$0.019 loss in 3Q 2020)

No longer forecast to breakeven

Second quarter 2021 earnings released: CA$0.041 loss per share (vs CA$0.034 loss in 2Q 2020)

Forecast to breakeven in 2023

It's Unlikely That Avivagen Inc.'s (CVE:VIV) CEO Will See A Huge Pay Rise This Year

Avivagen Inc. Announces Manuscript Reporting the Benefits of OxC-betaTM Livestock for Broiler Poultry Has Been Approved for Publication by Poultry Science

First quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.037 loss in 1Q 2020)

Revenue behind estimates

Avivagen Inc. Announces the Publication of Its New Zealand OxC-beta Livestock Dairy Trial for Use Against Sub-Clinical Mastitis

Avivagen Inc. has completed a Composite Units Offering in the amount of CAD 7.5 million.

New 90-day high: CA$0.67

Mimi's Rock Corp. and Avivagen Announce Launch of Dr. Tobias Beta Blend on Amazon.Com

Avivagen Inc., Annual General Meeting, Apr 08, 2021

Avivagen Inc. Announces Six Tonne Order of OxC-beta Livestock from New Customer in Mexico

New 90-day high: CA$0.66

Analysts update estimates

Revenue behind estimates

Full year 2020 earnings released: CA$0.12 loss per share

New 90-day high: CA$0.59

New 90-day high: CA$0.55

New 90-day low: CA$0.40

Avivagen Announces Record Four Tonne Order from UNAHCO

Avivagen Inc. Receives Multiple New Orders and Joins Influential Industry Associations in Mexico

Avivagen Inc. Receives 10 Tonne Purchase Order for OxC-Beta Livestock from Large North American Client

New 90-day high: CA$0.51

Analysts update estimates

Third quarter earnings released

New 90-day low - CA$0.41

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd